TSE:AUP - Aurinia Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started C$7.60 +0.02 (+0.26 %) (As of 07/22/2018 04:00 PM ET)Previous CloseC$7.60Today's RangeC$7.48 - C$7.6352-Week RangeC$5.68 - C$9.50Volume9,400 shsAverage Volume40,387 shsMarket CapitalizationC$596.22 millionP/E RatioN/ADividend YieldN/ABeta3.34 Company ProfileAnalyst RatingsEarnings HistoryInsider TradesHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada. Receive AUP News and Ratings via Email Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Technical & System Software Sub-IndustryN/A SectorComputer and Technology SymbolTSE:AUP CUSIPN/A Webwww.auriniapharma.com Phone+1-250-7084272 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-45,241.38% Return on Equity-30.41% Return on Assets-25.82% Miscellaneous EmployeesN/A Outstanding Shares84,200,000Market CapC$596.22 Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP." How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (TSE:AUP) posted its quarterly earnings results on Thursday, May, 10th. The company reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.02. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.07 million. Aurinia Pharmaceuticals had a negative return on equity of 30.41% and a negative net margin of 45,241.38%. View Aurinia Pharmaceuticals' Earnings History. When is Aurinia Pharmaceuticals' next earnings date? Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Aurinia Pharmaceuticals. What is the consensus analysts' recommendation for Aurinia Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of Aurinia Pharmaceuticals' key competitors? Some companies that are related to Aurinia Pharmaceuticals include Iress (IRE), Computer Modelling Group (CMG), GB Group (GBG), Emis Group (EMIS), Wandisco (WAND), SDL (SDL), Microgen (MCGN), Absolute Software (ABT), Dotdigital Group (DOTD), TECSYS (TCS), Ideagen (IDEA), iSentia Group (ISD), Smart Parking (SPZ), IDOX (IDOX) and Gresham Technologies (GHT). Who are Aurinia Pharmaceuticals' key executives? Aurinia Pharmaceuticals' management team includes the folowing people: Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 60)Mr. Michael R. Martin, Co-Founder & COOMr. Dennis Bourgeault C.A., CFO & Sec.Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.Dr. Neil Solomons M.D., Chief Medical Officer Has Aurinia Pharmaceuticals been receiving favorable news coverage? Headlines about AUP stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of 0.15 on Accern's scale. They also gave news headlines about the company an impact score of 45.55 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Aurinia Pharmaceuticals' stock price today? One share of AUP stock can currently be purchased for approximately C$7.60. How big of a company is Aurinia Pharmaceuticals? Aurinia Pharmaceuticals has a market capitalization of C$596.22 million. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272. MarketBeat Community Rating for Aurinia Pharmaceuticals (TSE AUP)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 116 (Vote Outperform)Underperform Votes: 84 (Vote Underperform)Total Votes: 200MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?